125 related articles for article (PubMed ID: 33301810)
1. Design and characterization of a recombinant immunotoxin for targeted therapy of breast cancer cells: In vitro and in silico analyses.
Barazesh M; Mohammadi S; Jalili S; Kavousipour S; Faraji SN; Mokarram P; Pirhadi S
Life Sci; 2021 Jan; 265():118866. PubMed ID: 33301810
[TBL] [Abstract][Full Text] [Related]
2. DFF40-iRGD, a novel chimeric protein with efficient cytotoxic and apoptotic effects against triple-negative breast cancer cells.
Amrollahi-Nia R; Akbari V; Shafiee F
Biotechnol Lett; 2021 Oct; 43(10):1967-1976. PubMed ID: 34482510
[TBL] [Abstract][Full Text] [Related]
3. GM-CSF-DFF40: a novel humanized immunotoxin induces apoptosis in acute myeloid leukemia cells.
Mathew M; Zaineb KC; Verma RS
Apoptosis; 2013 Jul; 18(7):882-95. PubMed ID: 23529188
[TBL] [Abstract][Full Text] [Related]
4. Two Simple Methods for Optimizing the Production of "Difficult-to-Express" GnRH-DFF40 Chimeric Protein.
Barazesh M; Mostafavipour Z; Kavousipour S; Mohammadi S; Mokarram P
Adv Pharm Bull; 2019 Aug; 9(3):423-431. PubMed ID: 31592077
[No Abstract] [Full Text] [Related]
5. Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231.
Aguilar-Rojas A; Huerta-Reyes M; Maya-Núñez G; Arechavaleta-Velásco F; Conn PM; Ulloa-Aguirre A; Valdés J
BMC Cancer; 2012 Nov; 12():550. PubMed ID: 23176180
[TBL] [Abstract][Full Text] [Related]
6. A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses.
Naemi AA; Salmanian AH; Noormohammadi Z; Amani J
Eur J Pharmacol; 2023 Sep; 955():175894. PubMed ID: 37429519
[TBL] [Abstract][Full Text] [Related]
7. Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein.
Ben-Yehudah A; Aqeilan R; Robashkevich D; Lorberboum-Galski H
Clin Cancer Res; 2003 Mar; 9(3):1179-90. PubMed ID: 12631624
[TBL] [Abstract][Full Text] [Related]
8. Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts disease-free and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression.
Banas T; Pitynski K; Okon K; Winiarska A
BMC Cancer; 2018 Apr; 18(1):418. PubMed ID: 29653556
[TBL] [Abstract][Full Text] [Related]
9. A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.
Rezaie E; Amani J; Bidmeshki Pour A; Mahmoodzadeh Hosseini H
Eur J Pharmacol; 2020 Mar; 870():172912. PubMed ID: 31926992
[TBL] [Abstract][Full Text] [Related]
10. Surface antigens/receptors for targeted cancer treatment: the GnRH receptor/binding site for targeted adenocarcinoma therapy.
Eaveri R; Ben-Yehudah A; Lorberboum-Galski H
Curr Cancer Drug Targets; 2004 Dec; 4(8):673-87. PubMed ID: 15578922
[TBL] [Abstract][Full Text] [Related]
11. Stable overexpression of DNA fragmentation factor in T-47D cells: sensitization of breast cancer cells to apoptosis in response to acetazolamide and sulfabenzamide.
Bagheri F; Safarian S; Eslaminejad MB; Sheibani N
Mol Biol Rep; 2014 Nov; 41(11):7387-94. PubMed ID: 25086620
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic activity of a recombinant GnRH-PAP fusion toxin on human tumor cell lines.
Schlick J; Dulieu P; Desvoyes B; Adami P; Radom J; Jouvenot M
FEBS Lett; 2000 Apr; 472(2-3):241-6. PubMed ID: 10788619
[TBL] [Abstract][Full Text] [Related]
13. Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor.
Qi L; Nett TM; Allen MC; Sha X; Harrison GS; Frederick BA; Crawford ED; Glode LM
Cancer Res; 2004 Mar; 64(6):2090-5. PubMed ID: 15026348
[TBL] [Abstract][Full Text] [Related]
14. DFF40 deficiency in cancerous T cells is implicated in chemotherapy drug sensitivity and resistance through the regulation of the apoptotic pathway.
Kulbay M; Johnson B; Fiola S; Diaz RJ; Bernier J
Biochem Pharmacol; 2021 Dec; 194():114801. PubMed ID: 34678222
[TBL] [Abstract][Full Text] [Related]
15. Survivin Promoter-Driven DFF40 Gene Expression Sensitizes Melanoma Cancer Cells to Chemotherapy.
Minaiyan G; Shafiee F; Akbari V
Int J Toxicol; 2021; 40(4):380-387. PubMed ID: 33960240
[TBL] [Abstract][Full Text] [Related]
16. Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH.
Gründker C; Bauerschmitz G; Schubert A; Emons G
Int J Oncol; 2016 Jun; 48(6):2713-21. PubMed ID: 27098123
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of breast cancer cells to doxorubicin via stable cell line generation and overexpression of DFF40.
Bagheri F; Safarian S; Eslaminejad MB; Sheibani N
Biochem Cell Biol; 2015 Dec; 93(6):604-10. PubMed ID: 26529233
[TBL] [Abstract][Full Text] [Related]
18. Recombinant GnRH-p53 protein sensitizes breast cancer cells to 5-fluorouracil-induced apoptosis in vitro and in vivo.
Lu Y; Zhang Z; Yan Z; Chen L; Deng W; Lotze M; Wang Z; Lin X; Li LY
Apoptosis; 2013 Oct; 18(10):1214-23. PubMed ID: 23801079
[TBL] [Abstract][Full Text] [Related]
19. Characterization of an intrinsically fluorescent gonadotropin-releasing hormone receptor and effects of ligand binding on receptor lateral diffusion.
Nelson S; Horvat RD; Malvey J; Roess DA; Barisas BG; Clay CM
Endocrinology; 1999 Feb; 140(2):950-7. PubMed ID: 9927328
[TBL] [Abstract][Full Text] [Related]
20. Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy.
Shariaty Vaziri Z; Shafiee F; Akbari V
Biotechnol Lett; 2023 Apr; 45(4):537-550. PubMed ID: 36807722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
